Development asset linked to NEURAXPHARM AUSTRALIA PTY in public FDA and regional records.
pharma · Refractory Partial Onset Epilepsy · Multiple Sclerosis
NEURAXPHARM AUSTRALIA PTY
NEURAXPHARM AUSTRALIA PTY LIMITED
NEURAXPHARM AUSTRALIA PTY drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Melbourne, AU HQ
11 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Employees
- 11
- Programs
- 3
- Drugs
- 17
- Patents
- 0
NEURAXPHARM AUSTRALIA PTY pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
NEURAXPHARM AUSTRALIA PTY drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to NEURAXPHARM AUSTRALIA PTY in public FDA and regional records.
-
dimethyl fumarate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Kelch-like ECH-associated protein 1.
- Target
- Kelch-like ECH-associated protein 1
- Mechanism
- Kelch-like ECH-associated protein 1 inhibitor
-
enoxaparin sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
Development asset linked to NEURAXPHARM AUSTRALIA PTY in public FDA and regional records.
-
Development asset linked to NEURAXPHARM AUSTRALIA PTY in public FDA and regional records.
-
Development asset linked to NEURAXPHARM AUSTRALIA PTY in public FDA and regional records.
-
guanfacine
Cardiovascular system (C02)Cardiovascular system (C02) compound in NEURAXPHARM AUSTRALIA PTY's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-2.
- Target
- Adrenergic receptor alpha-2
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
levetiracetam
Nervous system (N03)US regulatory status: approved. Molecular target: Synaptic vesicle glycoprotein 2A.
- Target
- Synaptic vesicle glycoprotein 2A
- Mechanism
- Synaptic vesicle glycoprotein 2A modulator
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
Development asset linked to NEURAXPHARM AUSTRALIA PTY in public FDA and regional records.
-
Development asset linked to NEURAXPHARM AUSTRALIA PTY in public FDA and regional records.
-
Development asset linked to NEURAXPHARM AUSTRALIA PTY in public FDA and regional records.
-
Development asset linked to NEURAXPHARM AUSTRALIA PTY in public FDA and regional records.
-
tegomil fumarate
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in NEURAXPHARM AUSTRALIA PTY's portfolio.
-
ublituximab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in NEURAXPHARM AUSTRALIA PTY's portfolio. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent